# Pfizer

Type: Company (PFE)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/pfizer
Canonical HTML page: https://getfinancebrief.com/entity/pfizer

## Recent coverage (5 stories)

### 2 Dirt-Cheap Dividend Stocks Yielding 6.5% and 5.8%: PFE and BMY for $1,000
2026-07-08 21:25:08 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

In a market where the S&P 500 yields a paltry 1.4%, Pfizer and Bristol Myers Squibb offer income investors a rare combination of outsized yields and deep value. With forward P/E ratios below 11, these beaten-down pharma giants could re-rate as pipeline successes materialize.
Full story: https://getfinancebrief.com/story/dirt-cheap-dividend-stocks-pfe-bmy-finance

### Pfizer's 6.9% Yield vs 1% S&P 500: Income Trap or Turnaround Play?
2026-06-28 01:10:24 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

With a 6.9% yield (vs 1% for the S&P 500) and a 130% payout ratio, Pfizer presents a classic risk-reward scenario for income portfolios. The stock’s 60% decline from 2021 highs prices in significant pessimism, but historical resilience may offer patient investors a favorable entry.
Full story: https://getfinancebrief.com/story/pfizer-dividend-yield-income-investing-analysis

### Quant-Rated Healthcare and Communication Services Stocks: Post-Earnings Winners
2026-03-14 15:23:39 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Seeking Alpha's post-earnings quant ratings for stocks above $10B market cap reveal a stark divergence between innovation-led growth and legacy value traps. While GLP-1 leaders and AI-driven ad platforms dominate the top rankings, traditional pharma and media outlets struggle with growth revisions and margin compression.
Full story: https://getfinancebrief.com/story/quant-rated-healthcare-comms-earnings-analysis-2026

### Biotech Earnings: Tarsus and ORIC Signal Growth Amid Clinical Milestones
2026-02-23 22:50:08 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Tarsus Pharmaceuticals and ORIC Pharmaceuticals reported fourth-quarter 2025 results, highlighting a pivotal shift toward commercial scaling and clinical data maturation. While Tarsus focuses on the rapid adoption of XDEMVY, ORIC is advancing its oncology pipeline with key data readouts expected in 2026.
Full story: https://getfinancebrief.com/story/tarsus-oric-biotech-earnings-q4-2025

### Pharma's 'Netflix' Pivot: Solving the Antibiotic Market Failure
2026-02-19 11:56:39 · Sentiment: Neutral · Impact: 7/10 · Sources: 3

Health experts and economists are advocating for a subscription-based 'Netflix' model for antibiotics to combat the rise of superbugs. This proposed shift aims to decouple pharmaceutical profits from sales volume, incentivizing R&D in a sector currently plagued by market failure.
Full story: https://getfinancebrief.com/story/antibiotics-subscription-model-superbugs-market-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.